Open Access

Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: A meta-analysis

  • Authors:
    • Hao Zhang
    • Yuchen Zhou
    • Guosheng Yuan
    • Guangyao Zhou
    • Dinghua Yang
    • Yuanping Zhou
  • View Affiliations

  • Published online on: July 30, 2015     https://doi.org/10.3892/mco.2015.614
  • Pages: 1239-1247
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the impact of postoperative antiviral treatment on tumor recurrence, fatalities and survival of patients with chronic hepatitis B virus (HBV) infection‑related primary hepatocellular carcinoma (HCC). A systematic meta‑analysis was performed. All the studies comparing nucleos(t)ide analogues (NAs) versus placebo or no treatment were considered. The results were expressed as relative ratio (RR) for 1‑, 3‑ and 5‑year recurrence‑free survival (RFS) and overall survival (OS), recurrence HCC and fatalities with 95% confidence intervals (CI) using STATA 11.0. In total, 15 trials with 7,619 patients were included. There were significant improvements for 1‑, 3‑ and 5‑year RFS (RR, 1.09; P=0.003; RR, 1.202; P<0.001; and RR, 1.219; P=0.02; respectively) and in 3‑ and 5‑year OS (RR, 1.087, P=0.006; and RR, 1.186; P<0.001) in the NAs group compared with the control group. Sensitivity analyses confirmed the robustness of the results. In addition, the significantly high rate of recurrence HCC and fatalities existed in the control group (RR, 1.301; P=0.002; and RR, 1.816, P<0.001). One study was for an entecavir (ETV)‑treated group compared with an adefovir (ADV)‑treated group and lamivudine (LAM)‑treated group. The 3‑year disease‑free survival rate for the ETV group was significantly better compared with the ADV and LAM groups [hazard ratio (HR), 0.810; P=0.049; and HR, 0.737; P=0.007]. The present study demonstrated the beneficial effects of NAs therapy following curative treatment of HBV‑related HCC. ETV may be the superior choice compared to ADV or LAM for the antiviral treatment.
View Figures
View References

Related Articles

Journal Cover

November-2015
Volume 3 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang H, Zhou Y, Yuan G, Zhou G, Yang D and Zhou Y: Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: A meta-analysis. Mol Clin Oncol 3: 1239-1247, 2015.
APA
Zhang, H., Zhou, Y., Yuan, G., Zhou, G., Yang, D., & Zhou, Y. (2015). Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: A meta-analysis. Molecular and Clinical Oncology, 3, 1239-1247. https://doi.org/10.3892/mco.2015.614
MLA
Zhang, H., Zhou, Y., Yuan, G., Zhou, G., Yang, D., Zhou, Y."Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: A meta-analysis". Molecular and Clinical Oncology 3.6 (2015): 1239-1247.
Chicago
Zhang, H., Zhou, Y., Yuan, G., Zhou, G., Yang, D., Zhou, Y."Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: A meta-analysis". Molecular and Clinical Oncology 3, no. 6 (2015): 1239-1247. https://doi.org/10.3892/mco.2015.614